{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-213439","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.353685+00:00","generated_at":"2026-05-14T21:03:34.732484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Operating expenses $9.9M, up 34% YoY; FDA grants RPD for (Z)-endoxifen in DMD and McCune-Albright","bullets":["Total operating expenses $9.9M in Q1 2026, up from $7.4M in Q1 2025, driven by higher legal fees for patent litigation (subsequently settled) and R&D costs.","R&D expenses $4.8M (+15% YoY) on increased clinical trial costs for (Z)-endoxifen; G&A $5.1M (+56%) due to $1.8M in patent litigation legal fees.","FDA granted Orphan Drug Designation (Jan 2026) and Rare Pediatric Disease designation for (Z)-endoxifen in Duchenne Muscular Dystrophy.","FDA granted Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome (May 2026), eligible for Priority Review Voucher (sold for $100-205M).","Atossa strengthened leadership with two new Medical Directors: Dr. Puyana Theall (Breast Oncology) and Dr. Giwa (Rare Diseases)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213439","json":"https://secwatch.observer/filing/0001193125-26-213439.json","markdown":"https://secwatch.observer/filing/0001193125-26-213439.md","text":"https://secwatch.observer/filing/0001193125-26-213439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/atos-20260508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:03:34.732484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1983a4143584a1cf12538091c9f9de4506c4ad80","claim":"ATOSSA THERAPEUTICS, INC. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-068983","ticker":"GMRS","company_name":"GMR Solutions Inc.","filed_at":"2026-06-01T20:45:55+00:00","headline":"GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068983","json":"https://secwatch.observer/filing/0001104659-26-068983.json","markdown":"https://secwatch.observer/filing/0001104659-26-068983.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/gmrs-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm"}},{"accession":"0001628280-26-039379","ticker":null,"company_name":"DAVEY TREE EXPERT CO","filed_at":"2026-06-01T17:50:11+00:00","headline":"Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039379","json":"https://secwatch.observer/filing/0001628280-26-039379.json","markdown":"https://secwatch.observer/filing/0001628280-26-039379.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/davey-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"Exchange Act, unless such subsequent filing specifically references this Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nTo Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm"}},{"accession":"0000029332-26-000027","ticker":"DXYN","company_name":"DIXIE GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029332-26-000027","json":"https://secwatch.observer/filing/0000029332-26-000027.json","markdown":"https://secwatch.observer/filing/0000029332-26-000027.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/dxyn-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm"}},{"accession":"0001043000-26-000016","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001043000-26-000016","json":"https://secwatch.observer/filing/0001043000-26-000016.json","markdown":"https://secwatch.observer/filing/0001043000-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/snda-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm"}},{"accession":"0001104659-26-058180","ticker":"URG","company_name":"UR-ENERGY INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058180","json":"https://secwatch.observer/filing/0001104659-26-058180.json","markdown":"https://secwatch.observer/filing/0001104659-26-058180.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1375205/000110465926058180/0001104659-26-058180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1375205/000110465926058180/urg-20260508x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1375205/000110465926058180/0001104659-26-058180-index.htm"}},{"accession":"0001104659-26-058204","ticker":"EXPI","company_name":"eXp World Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058204","json":"https://secwatch.observer/filing/0001104659-26-058204.json","markdown":"https://secwatch.observer/filing/0001104659-26-058204.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/agnt-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm"}},{"accession":"0001104659-26-058287","ticker":"BATRA","company_name":"Atlanta Braves Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Atlanta Braves Holdings Q1 revenue up 53% to $72M; operating loss narrows to $41M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058287","json":"https://secwatch.observer/filing/0001104659-26-058287.json","markdown":"https://secwatch.observer/filing/0001104659-26-058287.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/0001104659-26-058287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/batra-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"Total revenue grew to $72 million in the first quarter of 2026, up 53% from the prior year period.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/0001104659-26-058287-index.htm"}},{"accession":"0001193125-26-215645","ticker":"SBH","company_name":"Sally Beauty Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sally Beauty Q2 sales up 2.3%; GAAP EPS $0.43 beats year-ago $0.38; guidance range narrowed","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215645","json":"https://secwatch.observer/filing/0001193125-26-215645.json","markdown":"https://secwatch.observer/filing/0001193125-26-215645.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368458/000119312526215645/0001193125-26-215645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368458/000119312526215645/d76806d8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm","comparable_excerpt":"Consolidated net sales of $903 million, an increase of 2.3% compared to the prior year; • Consolidated comparable sales growth of 1.3%; • Global e-commerce sales increased 13% to $108 million, representing 12% of net sales; • GAAP gross margin expansion of 70 basis points to 52.7%; • Adjusted Gross Margin expansion of 80 basis points to 52.8%; • GAAP selling, general and administrative expenses of $404 million, an increase of $14 million compared to the prior year; • Adjusted Selling, General and Administrative Expenses of $404 million, an increase of $20 million compared to the prior year; • GAAP operating earnings of $72 million and GAAP operating margin of 8.0%; • Adjusted Operating Earnings of $73 million and Adjusted Operating Margin of 8.1%; • GAAP diluted net earnings per share of $0.43, an increase of 13% compared to the prior year;","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1368458/000119312526215645/0001193125-26-215645-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}